News

Issues include apparently diverted opioids and mislabeled medications

As the definition of ‘targeted’ therapies—especially in oncology—and as a component of companion diagnostics, biomarkers are creating opportunities in drug research and commercialization

Smart tag connects onboard intelligence with smartphone

30-day deadline for making an application to participate; in the EU, the FMD program is progressing

Diligent Health Solutions banks on experienced management

Will restricting use of rebates in federal programs carry over to commercial insurance?

A marketing challenge: how to make more adults aware of anti-bacterial booster shots

Expansions in the capability of supply chain participants to manage temperature-controlled pharmaceuticals

Senate and House committees begin the legislative process for addressing drug pricing

Even as the science behind the new therapies is getting established, payers are preparing for their extraordinary cost

Broader capabilities for refrigerated or cryogenic transport of cellular materials

Signs up Bayer Health for pulmonary hypertension and MS

Nov. 27, 2018, was to be a red-letter day in the 10-year program to implement an end-to-end pharma traceability system. Did industry meet the deadline?

Programs provide copay and other financial assistance

Field trial results to be unveiled at upcoming meeting

Partnership with Dacos A/S; FDA will look closer at cellular and genetic therapies

Spending on drug promotion rose—but not at the rate of pharma sales growth

Sandoz and Pear Therapeutics tackle opioid use disorder

Strengthening a leading player in track-and-trace packaging technology

A deeper commitment to oncology and immunology

List includes 25 orphan drugs; there were also seven additional biosimilars

Flu activity is “elevated” nationally; Walgreens sees a hotspot in Nebraska

Nearly a million US citizens live with HIV, a virus that still lacks a curative therapy

Cellular and genetic therapies (CGTs) developers are struggling to build capacity

Oncology represents half of the dollar volume of HDA-member sales

Pfizer’s Ibrance was the star performer from the class of 2015 FDA approvals

Action consolidates leading courier companies with larger freight forwarders